OpenAI, Founders Fund Back Coherence Neuro in $45 Million Round for Cancer-Detecting Brain Implants
Updated
Updated · WIRED · Oct 21
OpenAI, Founders Fund Back Coherence Neuro in $45 Million Round for Cancer-Detecting Brain Implants
1 articles · Updated · WIRED · Oct 21
Summary
$45 million in seed funding will help Coherence Neuro push an AI-powered brain implant toward clinical trials for glioblastoma, with OpenAI’s startup fund and Peter Thiel’s Founders Fund among the backers.
Coherence is building implants that decode electrical signals linked to brain tumors and deliver mild stimulation intended to halt growth, aiming for a device that learns to detect cancer and treat it in real time.
Three patients undergoing tumor-removal surgery in Australia have already worn the implant for about 30 minutes in an initial safety check, and the company is now testing recording and stimulation in seven more patients.
The deal extends Big Tech’s growing bet on brain-computer interfaces, but Coherence CEO Ben Woodington said OpenAI will not get access to the startup’s brain or health data.
OpenAI funded a brain-cancer implant but will not access its data—what hidden value does this bioelectric technology hold for tech giants?
If brain tumors hijack neural circuits to grow, could an AI-orchestrated electrical pulse literally hack the cancer to death?
AI Meets Oncology: Inside Coherence Neuro’s $45 Million Seed Round and the Rise of Continuous Bioelectric Cancer Implants
Overview
Coherence Neuro’s $45 million seed round, led by top tech investors, highlights a new trend: venture capitalists see brain-computer interfaces as powerful tools for generating continuous biological data that can fuel AI-driven cancer therapies. Their SOMA-1 implant, designed to disrupt tumor growth by delivering targeted electrical stimulation, builds on the insight that aggressive cancer cells form electrical connections with healthy neurons. Unlike traditional implants, SOMA-1 uses special materials to remain invisible during MRI scans, enabling ongoing monitoring. Advanced machine learning algorithms decode unique tumor signals in real time, supporting personalized, closed-loop treatment and paving the way for long-term clinical trials in glioblastoma and beyond.